Nosocomial MRSA Pneumonia: Data from Recent Clinical Trials

Author(s): M. Karvouniaris, D. Makris, D. Karabekos, E. Zakynthinos

Journal Name: Reviews on Recent Clinical Trials

Volume 6 , Issue 3 , 2011


Become EABM
Become Reviewer
Call for Editor

Abstract:

MRSA infections, especially pneumonia have been associated with considerable morbidity and mortality and the management of MRSA infections is considered as an issue of high priority for scientific societies. Many studies which have been published during the last 10 years have provided evidence for MRSA pneumonia epidemiology, diagnosis and treatment. The main regime of antibiotic treatment recommended for MRSA pneumonia is either vancomycin or linezolid. Despite its pK/pD superiority over vancomycin, linezolid has to date failed to show clear advantage over vancomycin in recent clinical trials.

Keywords: Pneumonia, MRSA, Vancomycin, Linezolid, EPIDEMIOLOGY, Prognosis, healthcare associated (HCAP), ventilator associated (VAP), Etiological diagnosis, water-soluble drug

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 6
ISSUE: 3
Year: 2011
Page: [235 - 240]
Pages: 6
DOI: 10.2174/157488711796575568
Price: $65

Article Metrics

PDF: 10